Ruxolitinib, a promising therapeutic candidate for traumatic brain injury through maintaining the homeostasis of cathepsin B-Reference-Cited by-全球学者库

Ruxolitinib, a promising therapeutic candidate for traumatic brain injury through maintaining the homeostasis of cathepsin B

Published:2023-05 Issue: Volume:363 Page:114347
ISSN:0014-4886
Container-title:Experimental Neurology
language:en
Short-container-title:Experimental Neurology

Author:

Peng Jianhang,Gao Cheng,Chen Xueshi,Wang Tao,Luo Chengliang,Zhang Mingyang,Chen Xiping,Tao Luyang

Funder

National Natural Science Foundation of China

Priority Academic Program Development of Jiangsu Higher Education Institutions

Publisher

Elsevier BV

Subject

Developmental Neuroscience,Neurology

Reference52 articles.

1. The lysosome: from waste bag to potential therapeutic target;Appelqvist;J. Mol. Cell Biol.,2013

2. Temporal and spatial profile of caspase 8 expression and proteolysis after experimental traumatic brain injury;Beer;J. Neurochem.,2001

3. Traumatic brain injury in mice deficient in bid: effects on histopathology and functional outcome;Bermpohl;J. Cereb. Blood Flow Metab.,2006

4. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial;Cao;J. Allergy Clin. Immunol.,2020

5. MicroRNA-133 overexpression promotes the therapeutic efficacy of mesenchymal stem cells on acute myocardial infarction;Chen;Stem Cell Res Ther,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Colloidal therapeutics in the management of traumatic brain injury: Portray of biomarkers and drug-targets, preclinical and clinical pieces of evidence and future prospects;Colloids and Surfaces B: Biointerfaces;2023-10